LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit October 2, 2020

Rhea-AI Summary

LogicBio Therapeutics, Inc. (Nasdaq: LOGC) announced that CEO Fred Chereau will present at the Jefferies Virtual Gene Editing/Therapy Summit on October 2, 2020, at 11:30 AM ET. The presentation will be available via a live audio webcast on LogicBio’s website, with a replay accessible one hour post-event for 30 days. The company specializes in genome editing to treat rare pediatric diseases, utilizing its GeneRide platform for site-specific therapeutic transgene integration, aiming to meet significant medical needs.

LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Jefferies Virtual Gene Editing/Therapy Summit on Friday, October 2, 2020 at 11:30 AM, ET.

A live audio webcast of the presentation will be available under the “Events and Presentations” section of LogicBio’s website. A replay of the presentation will become available approximately one hour after the event and will be archived for 30 days.

About LogicBio Therapeutics

LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive potential lifelong expression. Headquartered in Lexington, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.  For more information, please visit www.logicbio.com

Contacts:

Investors:
Matthew Lane

Gilmartin Investor Relation

matt@gilmartinir.com

Media:
Stephanie Simon

Ten Bridge Communications

Stephanie@tenbridgecommunications.com

617-581-9333

FAQ

When is the Jefferies Virtual Gene Editing/Therapy Summit for LOGC?

The Jefferies Virtual Gene Editing/Therapy Summit for LogicBio Therapeutics (LOGC) is on October 2, 2020, at 11:30 AM ET.

How can I access the LOGC presentation at the summit?

You can access the LOGC presentation via a live audio webcast on LogicBio's website under the 'Events and Presentations' section.

Will the LOGC presentation be available after the live event?

Yes, a replay of the LOGC presentation will be available approximately one hour after the event and archived for 30 days.

What technology does LogicBio Therapeutics use?

LogicBio Therapeutics uses GeneRide, a proprietary platform that enables site-specific integration of therapeutic transgenes through homologous recombination.

What is the focus of LogicBio Therapeutics?

LogicBio Therapeutics focuses on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs.